Thymosin Alpha1
Phase 3Small molecule
Thymosin Alpha1 is one of 131 small molecule programs targeting Sepsis. It is currently in Phase 3.
5
Indications
9
Total Trials
4
Active Trials
130
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Adrucil
EElorac, Inc.
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Tecentriq
RochePhase 3
Decadron
AAspen Global Incorporated
Phase 3
Mitosol
UUroGen Pharma Ltd.
Phase 3
Balstilimab
AAgenus Inc.
Phase 3
Calcium Folinate
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Thymosin Alpha1
SSun Yat-sen University
Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Combination Therapy1 trial
Colorectal Cancer1 trial
4 more indications
Rheumatic Heart Disease1 trial
Recurrent Implantation Faliure1 trial
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thymosin Alpha1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSun Yat-sen University